Vertex bows out of hepatitis C race to focus on cystic fibrosis
This article was originally published in Scrip
Vertex Pharmaceuticals wrote off its experimental hepatitis C drug VX-135, saying the drug has no value, as the company exits a highly competitive field to double down on its cystic fibrosis program.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.